THERAPY DOSSIER · th-3d8e7769f3c2

Bone morphogenetic protein 4 (BMP4), administered as exogenous BMP4; BMP4 siRNA knockdown and BMP4+/- mice used as loss-of-function comparators

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02869243 ↗Injury indicationPHASE1completed

A Dose Escalation Phase I Study Of Human-Recombinant Bone Morphogenetic Protein 4 Administrated Via Convection-Enhanced Delivery In Patients With Progressive And/Or Multiple Recurrent Glioblastoma Multiforme

Glioblastoma

Enrolment: 15 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25142202 ↗2014Mixed findings

Bone morphogenetic protein 4 inhibits liposaccharide-induced inflammation in the airway.

MixedEndotoxin/LPSC57BL/6 background; BMP4 mutant (BMP4+/-) mice compared with BMP4+/+ littermates

Model: Lipopolysaccharide (LPS)-induced acute airway inflammation, chronic LPS exposure, and Pseudomonas aeruginosa lung infection; LPS or TNF-alpha stimulation of airway epithelial cells and peritoneal macrophages in vitro

BMP4 was upregulated in LPS-inflamed lungs and in airway epithelial cells treated with LPS or TNF-alpha. BMP4+/- mice showed more severe lung inflammation and lower bacterial load after LPS or Pseudomonas aeruginosa than BMP4+/+ mice, and BMP4 knockdown increased LPS and TNF-alpha induced IL-8 in 1…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…